The results of a new study conducted could have an impact on the treatment of multiple sclerosis and other autoimmune diseases, which affect tens of thousands of people.
Gilead Sciences, Inc. announced receipt of a Paragraph IV Certification Notice Letter advising that Sigmapharm Laboratories, LLC submitted an Abbreviated New Drug Application (ANDA) to the FDA requesting permission to manufacture and market a generic version of Hepsera.
Protalex, Inc. announced the dosing of the first patient in a multicenter Phase 1b clinical study of PRTX-100 in adult patients with active rheumatoid arthritis.
Many drug stores are offering flu shots earlier than in past years in line with a federal recommendation that everyone older than six months be vaccinated this season.
A group of federal health experts narrowly voted to expand approval of a best-selling antidepressant, though panelists disagreed over which types of pain the pill effectively treats.
KIYATEC Inc. has launched the first in a series of KIYAKUBE 3D Cell Culture Plasticware. This technology platform provides a universal and cost effective method which enables three-dimensional cell culture.
Mirrorball from TTP Labtech is the first microplate cytometer to offer simultaneous laser scanning, enabling superior multiplexing and resulting in higher throughput single pass scanning.
The thermo-reversible hydrogel mountant CyGEL from Biostatus Ltd. offers a new, simplified method for the micro-injection of zebrafish embryos.
Transposagen Biopharmaceuticals, Inc. has added 170 genetically modified rats and related biomaterials to its database of laboratory rats with a genetic modification that can mimic a human disease.
ClinTec International, a global clinical research organisation (CRO) announces a financial and strategic partnership with Elephant Capital Plc., an AIM market listed private equity firm.
Immunomedics, Inc. and GE Healthcare announced that they have entered into a license and collaboration agreement for the evaluation of labeling technologies based on Immunomedics' patented F-18 peptide labeling method.
A team of scientists has found that suppressing a newly discovered gene lengthens the lifespan of roundworms. The results offer promising early evidence that scientists may succeed at finding targets for drugs that someday could allow people to live longer, healthier lives.
Researchers have determined that the use of drug-eluting stents improves the long-term clinical outcome for patients undergoing percutaneous coronary intervention, commonly known as angioplasty.
Clavis Pharma, the Norwegian cancer drug development company, announces that it has recruited the first patient into its pivotal Phase 3 study assessing its lead product elacytarabine in patients with late-stage acute myeloid leukemia.
ImmunoGen, Inc., a developer of antibody-based targeted anticancer products, announced that the FDA has granted orphan drug designation to lorvotuzumab mertansine when used for the treatment of small-cell lung cancer (SCLC).